Patents by Inventor Elmer J. Mirro

Elmer J. Mirro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating disorders of calcium homeostasis
    Publication number: 20040082588
    Abstract: The present invention provides methods for using tricyclic amide compounds, such as 1
    Type: Application
    Filed: September 29, 2003
    Publication date: April 29, 2004
    Applicant: Schering Corporation
    Inventors: Ellen W. Evans, Wai Nang Choy, Elmer J. Mirro
  • Use of neurokinin receptor antagonists to treat androgen-dependent diseases
    Patent number: 6569872
    Abstract: Use of an antagonist selected from the group consisting of: (a) antagonists of neurokinin-1 (NK1), neurokinin-2 (NK2) and neurokinin-3 (NK3) receptors, (b) antagonists of NK1 and NK2 receptors, (c) antagonists of NK2 and NK3 receptors, (d) antagonists of NK1 and NK3 receptors, (e) antagonists of NK1 receptors, and (f) antagonists of NK2 to treat symptoms and disorders associated with a production and/or secretion of androgen. One aspect of the invention relates to the use of antagonists to suppress production/secretion of androgens in mammals suffering from an androgen-dependent disease, such as benign prostatic hyperplasia and prostatic carcinoma.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: May 27, 2003
    Assignee: Schering Corporation
    Inventors: Michael W. Leach, Mark R. Berardi, Elmer J. Mirro, Dineshwar Sinha, Jonathan A. Pachter, Mark E. Cartwright, Gregory A. Reichard
  • Use of neurokinin receptor antagonists to treat androgen-dependent diseases
    Publication number: 20030092602
    Abstract: Use of an antagonist selected from the group consisting of: (a) antagonists of neurokinin-1 (NK1), neurokinin-2 (NK2) and neurokinin-3 (NK3) receptors, (b) antagonists of NK1 and NK2 receptors, (c) antagonists of NK2 and NK3 receptors, (d) antagonists of NK1 and NK3 receptors, (e) antagonists of NK1 receptors, and (f) antagonists of NK2 to treat symptoms and disorders associated with a production and/or secretion of androgen. One aspect of the invention relates to the use of antagonists to suppress production/secretion of androgens in mammals suffering from an androgen-dependent disease, such as benign prostatic hyperplasia and prostatic carcinoma.
    Type: Application
    Filed: May 7, 2002
    Publication date: May 15, 2003
    Applicant: Schering Corporation
    Inventors: Michael W. Leach, Mark R. Berardi, Elmer J. Mirro, Dineshwar Sinha, Jonathan A. Pachter, Mark E. Cartwright, Gregory A. Reichard
  • Imidazoles as cholesterol lowering agents
    Patent number: 6297268
    Abstract: In one embodiment, the present invention discloses a method and pharmaceutical composition for lowering serum cholesterol in a patient. The method comprises administering to the patient a pharmaceutical composition comprising a therapeutically effective cholesterol lowering amount of an imidazole.
    Type: Grant
    Filed: November 30, 1999
    Date of Patent: October 2, 2001
    Assignee: Schering Corporation
    Inventors: Ellen W. Evans, Eileen A. Snyder, Elmer J. Mirro, Carol Merrill